Melt Granulation

Author(s):  
Shana Van de Steene ◽  
Valérie Vanhoorne ◽  
Chris Vervaet ◽  
Thomas De Beer
Keyword(s):  
1997 ◽  
Vol 45 (3) ◽  
pp. 518-524 ◽  
Author(s):  
Toru MAEJIMA ◽  
Takashi OSAWA ◽  
Kingo NAKAJIMA ◽  
Masao KOBAYASHI
Keyword(s):  

1991 ◽  
Vol 111 (9) ◽  
pp. 515-523 ◽  
Author(s):  
Yasuo HARAMIISHI ◽  
Yoshio KITAZAWA ◽  
Manabu SAKAI ◽  
Katsuo KATAOKA
Keyword(s):  

2008 ◽  
Vol 13 (5) ◽  
pp. 401-411 ◽  
Author(s):  
C.V. Liew ◽  
Z.H. Loh ◽  
P.W.S. Heng ◽  
C.C. Lee
Keyword(s):  

2018 ◽  
Vol 4 (2) ◽  
pp. 139-149 ◽  
Author(s):  
Ankita U. Patel ◽  
Dipti V. Caudhari ◽  
Pranav J. Shah ◽  
Shailesh A. Shah

INDIAN DRUGS ◽  
2013 ◽  
Vol 50 (03) ◽  
pp. 5-13
Author(s):  
U.S Desai ◽  
◽  
P.D Chaudhari ◽  
D.B. Bhavsar ◽  
R.P. Chavan

Melt granulation is a size enlargement process in which the addition of a binder that melts or softens at relatively low temperatures (about 60o C) is used to achieve agglomeration of solid particles in the formulation. The process utilizes materials that are effective as granulating agents when they are in the softened or molten state. This process can be used for the preparation of sustained released dosage forms by using lipophilic polymers, such as glycerol monostearate, a combination of a hydrophobic material such as a starch derivative and stearic acid. It also can be used to prepare fast release melt granules by utilizing water-soluble polymers and surfactants, such as PEG and poloxomers. Melt granulation is one of the most widely applied processing techniques in the array of pharmaceutical manufacturing operations.


INDIAN DRUGS ◽  
2018 ◽  
Vol 55 (02) ◽  
pp. 68-71
Author(s):  
N. C Ratnakara ◽  
◽  
M. C. Gohel

The objective of the present study was to identify critical formulation parameters affecting the drug release from modified release wax matrix tablet of milnacipran hydrochloride employing the concept of design of experiments.The optimized amount of Compritol 888 ATO(intragranular) (X1), lactose (X2) and Compritol 888ATO (extragranular)(X3) were determined employing simplex latticedesign. The tablets were prepared using melt granulation technique. The in vitro drug release study was carried out in an acidic medium (pH 1.2) for 2 h and thereafter the dissolution study was conducted in phosphate buffer (pH 6.8).The selected dependent variables were the cumulative percentage of milnacipran hydrochloride dissolved at 1 (Y1), 8 (Y8), 16 (Y16) and 24 h (Y24). Mathematical models, correlating the independent variables with dependent variables were evolved. Optimization was performed for the three independent variables using the stated target ranges; Y1≤20%; Y8=45±5%; Y16=72±5%; Y24=100%. The optimized amounts of Compritol ATO888 (intragranular)(X1), lactose (X2) and Compritol 888ATO (extragranular)(X3), were found to be 60, 55 and 30 mg, respectively.The optimized formulation showed a release profile that was close to the predicted values. The drug was released by anomalous diffusion from the optimized formulation. Compritol 888ATO (intragranular) (X1), lactose (X2) and Compritol 888ATO(extragranular) (X3) were identified as critical variables.


Sign in / Sign up

Export Citation Format

Share Document